Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Rong JiangZhi-Cheng Jing

Abstract

The in-hospital mortality of severe pulmonary hypertension (PH) with right heart failure (RHF) is high despite the use of vasoactive and PH-specific therapies. We conducted a prospective analysis evaluating the safety and outcomes of fasudil hydrochloride (Chuan Wei) therapy in acute RHF. PH patients hospitalized between April 2009 and November 2010 were treated with 30 mg of i.v. fasudil three times daily over 30 min, until they experienced relief of RHF symptoms. Adverse and serious adverse events were recorded. Odds ratios (ORs) and 95% confidence intervals were calculated for both in-hospital mortality and re-hospitalization. Multivariate adjustments were made for age, gender and World Health Organization functional class. There were no significant differences between the fasudil group and the control group in demographics, hemodynamics, and PH-specific and vasoactive therapies. Of the 209 study patients, 3 of the 74 patients (4.1%) in the fasudil arm died, and 19 of the 135 patients (14.1%) in the control arm died (P=0.005). Fasudil decreased both in-hospital mortality (OR=0.258 (0.074-0.903); P=0.034) and 30-day re-hospitalization (OR=0.200 (0.059-0.681); P=0.010). Fasudil was well tolerated; one patient discontinued trea...Continue Reading

References

May 1, 1975·British Heart Journal·E L HollowayD C Harrison
Nov 1, 1990·Respiratory Medicine·P J ChapmanS R Benatar
Jan 9, 1997·The New England Journal of Medicine·L J Rubin
May 1, 1997·Cardiovascular Research·M Rabinovitch
Feb 24, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Karen A FaganIvan F McMurtry
Apr 9, 2004·Critical Care Medicine·François KerbaulSerge Brimioulle
Oct 2, 2004·The New England Journal of Medicine·Marc HumbertGérald Simonneau
Jan 6, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Yoshitaka Hirooka, Hiroaki Shimokawa
Jun 18, 2005·Circulation Research·Jean-Marc HyvelinPaul McLoughlin
Jan 26, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Ken IshikuraTakeshi Nakano
Nov 28, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Fuhai LiRuopeng Sun
Feb 22, 2007·Journal of Cardiovascular Pharmacology·Bao Hua JiangHiroaki Shimokawa
Apr 6, 2007·The Tohoku Journal of Experimental Medicine·Yoshihiro FukumotoHiroaki Shimokawa
Jul 9, 2009·Journal of the American College of Cardiology·Robyn J BarstNazzareno Galiè
Jul 11, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Zhulanqiqige Do eHiroaki Shimokawa
Nov 10, 2009·The European Respiratory Journal·B SztrymfM Humbert
Nov 26, 2010·American Journal of Respiratory and Critical Care Medicine·Steven M Hollenberg
Feb 12, 2011·The European Respiratory Journal·A CampoP M Hassoun
Mar 12, 2011·Expert Opinion on Investigational Drugs·Ralph T SchermulyHossein Ardeschir Ghofrani
Sep 27, 2012·Progress in Cardiovascular Diseases·Hooman D Poor, Corey E Ventetuolo
Aug 6, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshihiro FukumotoHiroaki Shimokawa
Oct 4, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Qiang GuoJason X-J Yuan
Dec 21, 2013·Journal of the American College of Cardiology·Marius M HoeperDavid B Badesch
Mar 22, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yugang ZhuangWei Zhao
Mar 22, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Akihiro HirashikiToyoaki Murohara

❮ Previous
Next ❯

Citations

Jun 3, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Toru Shimizu, James K Liao
Nov 20, 2015·BioMed Research International·Ayodeji AdegunsoyeOlusegun Oyenuga
Sep 2, 2016·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Qiang GuoJian-An Huang
Nov 17, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Laurent SavaleMarc Humbert
Jan 8, 2020·Expert Opinion on Therapeutic Targets·Brian YuJames K Liao
Nov 12, 2019·British Journal of Pharmacology·Astrid WeissRalph T Schermuly
Jun 23, 2020·Oxidative Medicine and Cellular Longevity·Damian GajeckiAdrian Doroszko

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.